699 results on '"Mougiakakos, Dimitrios"'
Search Results
2. Metabolic rewiring promotes anti-inflammatory effects of glucocorticoids
3. Neutrophil-specific expression of JAK2-V617F or CALRmut induces distinct inflammatory profiles in myeloproliferative neoplasia
4. Activating mutations in JAK2 and CALR differentially affect intracellular calcium flux in store operated calcium entry
5. CT-defined sarcopenia predicts treatment response in primary central nervous system lymphomas
6. AML consolidation therapy: timing matters
7. Low subcutaneous adipose tissue and myosteatosis are prognostic factors after allogeneic hematopoietic stem cell transplantation
8. Synergistic lethality in chronic myeloid leukemia – targeting oxidative phosphorylation and unfolded protein response effectively complements tyrosine kinase inhibitor treatment
9. CD4+ T cell-induced inflammatory cell death controls immune-evasive tumours
10. Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib
11. Impact of FLT3-ITD location on cytarabine sensitivity in AML: a network-based approach
12. Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experience
13. A key role of the WEE1-CDK1 axis in mediating TKI-therapy resistance in FLT3-ITD positive acute myeloid leukemia patients
14. Long-Term Survivors after Failure of Chimeric Antigen Receptor T Cell Therapy for Large B Cell Lymphoma: A Role for Allogeneic Hematopoietic Cell Transplantation? A German Lymphoma Alliance and German Registry for Stem Cell Transplantation Analysis
15. CAR T-cell therapy in autoimmune diseases
16. Author Correction: Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
17. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
18. B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases
19. Selective CAR-T cell mediated B cell depletion suppresses interferon signature in SLE
20. Treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR T cells
21. Successful Treatment of Concomitant Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome with Autologous CD19-targeted CAR-T Cells (P4-14.006)
22. Bone marrow stroma cells promote induction of a chemoresistant and prognostic unfavorable S100A8/A9high AML cell subset
23. GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany
24. The metabolic profile of reconstituting T-cells, NK-cells, and monocytes following autologous stem cell transplantation and its impact on outcome
25. Hypogammaglobulinemia and Anti-CD20 Therapy-Induced Acute Thrombocytopenia: Perhaps More than a Coincidence?
26. Increased PD-1 Expression on Circulating T Cells Correlates with Inferior Outcome after Autologous Stem Cell Transplantation
27. None: Unveiling the signaling network of FLT3-ITD AML improves drug sensitivity prediction
28. Unveiling the signaling network of FLT3-ITD AML improves drug sensitivity prediction
29. CD19 CAR T-Cell Therapy in Autoimmune Disease — A Case Series with Follow-up
30. Enhanced potency of immunotherapy against B‐cell precursor acute lymphoblastic leukemia by combination of an Fc‐engineered CD19 antibody and CD47 blockade
31. Relevance of different prognostic scores in primary CNS lymphoma in the era of intensified treatment regimens: A retrospective, multicenter analysis of 174 patients
32. Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas
33. Multi-omics reveals clinically relevant proliferative drive associated with mTOR-MYC-OXPHOS activity in chronic lymphocytic leukemia
34. Impact of Nrf2 expression in reconstituting T-cells of allogeneic hematopoietic stem cell transplanted patients
35. Successful use of anti-CD19 CAR T cells in severe treatment-refractory stiff-person syndrome.
36. Parameters of body composition do not predict survival in patients with multiple myeloma undergoing autologous stem cell transplantation.
37. Exploitable metabolic dependencies in MLL-ENL–induced leukemia
38. Anti-CD19 CAR T cells for refractory myasthenia gravis
39. Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R/R DLBCL
40. CAR T cells for treating autoimmune diseases
41. Unveiling the signaling network of FLT3-ITD AML improves drug sensitivity prediction
42. Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRST registry study
43. “Moonlighting” at the power plant: how mitochondria facilitate serial killing by CD8+ cytotoxic T cells
44. NK-Myeloid Cell Interactions in the Tumor Microenvironment: Implications for Cancer Immunotherapy
45. PGAM5 is a key driver of mitochondrial dysfunction in experimental lung fibrosis
46. P445: A SYSTEMS-BASED APPROACH TO UNVEIL DRUG RESISTANCE IN FLT3-ITD AML
47. P1004: ACTIVATING MUTATIONS IN JAK2 AND CALR DIFFERENTIALLY AFFECT INTRACELLULAR CALCIUM LEVELS AND CALCIUM FLUX
48. Induction treatment in high-grade B-cell lymphoma with a concurrent MYC and BCL2 and/or BCL6 rearrangement: a systematic review and meta-analysis
49. A novel immunoregulatory function of beta-2-microglobulin as a promoter of myeloid derived suppressor cell induction
50. Lenalidomide enhances MOR202-dependent macrophage-mediated effector functions via the vitamin D pathway
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.